SEC Form SC 13G filed by CorMedix Inc.

$CRMD
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CRMD alert in real time by email
SC 13G 1 tm226647d2_sc13g.htm SC 13G

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. __)*

 

CorMedix Inc.

(Name of Issuer)

 

Common stock, $0.001 par value

(Title of Class of Securities)

 

21900C308

(CUSIP Number)

 

December 31, 2021

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  x Rule 13d-1(b)
     
  ¨ Rule 13d-1(c)
     
  ¨ Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 21900C308 13G Page 2 of 9 Pages

 

1.

Names of Reporting Persons

 

Nomura Holdings, Inc.

2. Check the Appropriate Box if a Member of a Group (See Instructions)
  (a)  ¨
  (b)  ¨
3. SEC Use Only
4. Citizenship or Place of Organization:  Japan

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power     0

 

6. Shared Voting Power   2,003,612 (1)

 

7. Sole Dispositive Power 0

 

8. Shared Dispositive Power 2,003,612 (1)

9. Aggregate Amount Beneficially Owned by Each Reporting Person   
  2,003,612
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
  Not applicable
11. Percent of Class Represented by Amount in Row (9)  
  5.3% (2)
12. Type of Reporting Person (See Instructions)
  HC

 

(1)This represents 2,003,612 shares beneficially owned by Nomura Global Financial Products, Inc. (“NGFP”). NGFP is a wholly owned subsidiary of Nomura Holdings, Inc., which accordingly may be deemed to beneficially own the shares beneficially owned by NGFP.

 

(2)The percent of class is calculated based on 38,086,437 shares of common stock issued and outstanding as of November 5, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 filed with the SEC on November 9, 2021.

 

 

 

 

CUSIP No. 21900C308 13G Page 3 of 9 Pages

 

1.

Names of Reporting Persons

 

Nomura Global Financial Products, Inc.

2. Check the Appropriate Box if a Member of a Group (See Instructions)
  (a)  ¨
  (b)  ¨
3. SEC Use Only
4. Citizenship or Place of Organization:  Delaware

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power     0

 

6. Shared Voting Power   2,003,612

 

7. Sole Dispositive Power 0

 

8. Shared Dispositive Power 2,003,612

9. Aggregate Amount Beneficially Owned by Each Reporting Person   
  2,003,612
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
  Not applicable
11. Percent of Class Represented by Amount in Row (9)  
  5.3% (3)
12. Type of Reporting Person (See Instructions)
  BD

 

(3)The percent of class is calculated based on 38,086,437 shares of common stock issued and outstanding as of November 5, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 filed with the SEC on November 9, 2021.

 

 

 

CUSIP No. 21900C308 13G Page 4 of 9 Pages

 

Item 1. (a)

Name of Issuer:

 

CorMedix Inc.

     
  (b)

Address of Issuer's Principal Executive Offices:

 

300 Connell Drive, Suite 4200

Berkeley Heights, NJ 07922

 
Item 2. (a)

Name of Person(s) Filing:

Nomura Holdings, Inc.

Nomura Global Financial Products, Inc.

     
  (b)

Address of Principal Business Office or, if none, Residence:
Nomura Holdings, Inc.

13-1, Nihonbashi 1-chome, Chuo-ku, Tokyo 103-8645, Japan

 

Nomura Global Financial Products, Inc.

Worldwide Plaza

309 West 49th Street

New York, NY 10019

     
  (c)

Citizenship:
Nomura Holdings, Inc.

Japan

 

Nomura Global Financial Products, Inc.

Delaware

     
  (d)

Title of Class of Securities:

 

Common Stock, par value $0.001

     
  (e)

CUSIP Number:

 

21900C308

 
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  (a) x Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
       
  (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j) ¨  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
       
  (k) ¨

Group, in accordance with § 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________

 

 

 

CUSIP No. 21900C308 13G Page 5 of 9 Pages

 

Item 4.

Ownership.

 

  Items 5-11 of the cover page are incorporated by reference
 
Item 5. Ownership of Five Percent or Less of a Class.
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
   
Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 
Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

See Exhibit B

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable

 
Item 9.

Notice of Dissolution of Group.

 

Not applicable

 

 

 

 

CUSIP No. 21900C308 13G Page 6 of 9 Pages

 

Item 10. Certification.
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

SIGNATURE

 

After reasonable inquiry and to the best of the knowledge and belief of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

EXECUTED as a sealed instrument this 14th day of February, 2022.

 

  Nomura Holdings, Inc.
   
  /s/ Samir Patel
  Name: Samir Patel
  Title: Managing Director
   
  Nomura Global Financial Products, Inc.
   
  /s/ Samir Patel
  Name: Samir Patel
  Title: Authorized Officer

 

 

 

 

CUSIP No. 21900C308 13G Page 7 of 9 Pages

 

Index to Exhibits

 

Exhibit   Exhibit
A      Joint Filing Agreement
B        Subsidiaries

 

 

 

 

CUSIP No. 21900C308 13G Page 8 of 9 Pages

 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of this Schedule 13G with respect to the Securities of the Issuer and further agree that this Joint Filing Agreement be included as an exhibit to this Schedule 13G. In evidence thereof, the undersigned hereby execute this Joint Filing Agreement as of February 14, 2022.

 

Nomura Holdings, Inc.  
   
/s/ Samir Patel  
Name: Samir Patel  
Title: Managing Director  
   
Nomura Global Financial Products, Inc.  
   
/s/ Samir Patel  
Name: Samir Patel  
Title: Authorized Officer  

 

 

 

 

CUSIP No. 21900C308 13G Page 9 of 9 Pages

 

EXHIBIT B

 

SUBSIDIARIES

 

Nomura Global Financial Products, Inc. is a wholly owned subsidiary of Nomura Holdings, Inc.

 

 

 

 

Get the next $CRMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRMD

DatePrice TargetRatingAnalyst
3/7/2025$18.00Outperform
Leerink Partners
1/13/2025$15.00Buy
D. Boral Capital
8/26/2024$13.00Buy
Rodman & Renshaw
8/10/2023$6.00Outperform
RBC Capital Mkts
More analyst ratings

$CRMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    ‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

    BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am ETDomestic: 1-844-481-2557International: 1-412-317-0561Conference ID: 10197392Webcast: Webcast Link    About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and comme

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

    BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access to critical therapies for the estimated 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. This engagement leverages WSI PBG's proven expertis

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CRMD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CRMD
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRMD
SEC Filings

See more

$CRMD
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CRMD
Leadership Updates

Live Leadership Updates

See more
  • CorMedix Inc. Announces Appointment of Chief Legal Officer

    BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CorMedix Inc. Announces Partnership With The Leapfrog Group

    – CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

    BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors. Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent. "We are pleased to welcome Rob Stewart to the CorMedix Board," said Joseph Todisco, Chief Executive Officer of CorMedix. "Rob's deep experience in global pharmaceutical management and broad professional network in the pharma space will be inval

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CRMD
Financials

Live finance-specific insights

See more
  • CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    ‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

    BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am ETDomestic: 1-844-481-2557International: 1-412-317-0561Conference ID: 10197392Webcast: Webcast Link    About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and comme

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

    ‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) --  CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its first full quarter of DefenCath sales since commencing outpatient launch in July 2024. The Com

    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CRMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more